Premium
Measuring Platelet Aggregation in Dialysis Patients With a Whole Blood Aggregometer by the Screen Filtration Pressure Method
Author(s) -
Waki Kayo,
Hayashi Aki,
Ikeda Shigeo,
Ikeda Sadao,
Nagatsuka Kazuhiro,
Honma Yoshiyuki,
Kadowaki Takashi,
Yoshinoya Sadayoshi
Publication year - 2011
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2010.00899.x
Subject(s) - medicine , diabetes mellitus , dialysis , platelet , hemodialysis , blood pressure , renal function , platelet aggregation , whole blood , gastroenterology , surgery , endocrinology
A semi‐automatic, whole‐blood aggregometer based on the screen filtration pressure (SFP) method is now widely used clinically and in research, but has not been used with hemodialysis (HD) patients. We measured whole‐blood platelet aggregation in HD patients by the SFP method. This retrospective cross‐sectional study included 62 HD patients, of whom 47 were non‐diabetic and 15 were diabetic; we also included a control group of healthy, non‐uremic subjects. With the t ‐test, we examined differences in the platelet aggregation threshold index (PATI) in meaningful sub‐groupings of the HD patients, depending on whether or not they had diabetes, and whether or not they had been given antiplatelet agents. Considering the non‐diabetic HD patients first, their PATI values were significantly higher than those values in the control subjects (3.1 [1.0–5.2] vs. 1.8 [1.3–2.3] µM, P < 0.001). The non‐diabetic HD patients taking antiplatelet agents showed significantly (1.9 times) higher PATI values than the non‐diabetic HD patients without antiplatelet agents (4.4 [1.8–7.0] vs. 2.3 [1.3–3.3] µM, P = 0.003). We observed similar trends among diabetic HD patients. Whole‐blood analysis by the SPF method seems to be a promising way of monitoring platelet function for HD patients.